SCHEMBL3388441

SCHEMBL3388441

CCOc1ccccc1C(=O)/N=c1\sc2ccccc2n1CCOC

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.53
CNR2 P34972 3/20 0.53
RAB9A P51151 1/20 0.52
HPGD P15428 8/20 0.49
KDM4E B2RXH2 8/20 0.49
ALDH1A1 P00352 5/20 0.49
MAPT P10636 5/20 0.49
NPSR1 Q6W5P4 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
GAA P10253 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 2/20 0.47
KMT2A Q03164 3/20 0.47
TSHR P16473 1/20 0.44
TP53 P04637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3388446 1.00 CNR1 (0.53) CNR1CNR2RAB9AHPGDKDM4E
SCHEMBL3383559 0.85 RAB9A (0.55) CNR1CNR2RAB9AHPGDKDM4E
SCHEMBL3383551 0.85 RAB9A (0.55) CNR1CNR2RAB9AHPGDKDM4E
SCHEMBL3387250 0.84 PIM1 (0.56) CNR1CNR2RAB9AHPGDKDM4E
SCHEMBL3387253 0.84 PIM1 (0.56) CNR1CNR2RAB9AHPGDKDM4E
SCHEMBL3387209 0.84 RAB9A (0.55) CNR1CNR2RAB9AHPGDKDM4E
SCHEMBL3387213 0.84 RAB9A (0.55) CNR1CNR2RAB9AHPGDKDM4E
SCHEMBL3387630 0.82 CNR2 (0.74) CNR1CNR2RAB9AHPGDKDM4E
SCHEMBL15135232 0.82 RAB9A (0.53) CNR1CNR2RAB9AHPGDKDM4E
SCHEMBL15135230 0.82 RAB9A (0.53) CNR1CNR2RAB9AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841334-B2 Compounds as cannabinoid receptor ligands and uses thereof ABBVIE INC. (US) 2014-09-23 US disclosed
US-8546583-B2 Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide ABBVIE INC. (US) 2013-10-01 US disclosed
EP-2222165-B1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBVIE INC (US) 2013-07-31 EP disclosed
US-20100093814-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2010-04-15 US disclosed
US-20080058335-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBVIE INC. 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093814-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, OPRL1 CNR1 1/4885CNR2 2/4885RAB9A 1297/4885
US-20080058335-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, OPRL1 CNR1 1/4885CNR2 2/4885RAB9A 1315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.